Standard Biotools (LAB) Other financing activities (2010 - 2026)

Standard Biotools (LAB) has reported Other financing activities for 17 consecutive years, with $42000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities fell 86.36% year-over-year to $42000.0 in Q2 2026; TTM through Jun 2026 was $343000.0, a 15.93% decrease from a year earlier, with the FY2025 full-year figure at $531000.0, down 53.91% from the prior year.
• Other financing activities was $42000.0 for Q2 2026 at Standard Biotools, down from $78000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $980000.0 in Q2 2024 and troughed at $32000.0 in Q4 2024.
• A 5-year average of $252300.0 and a median of $150500.0 in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities plunged 91.94% in 2024 and soared 596.88% in 2025, its largest moves.
• Over 5 years, Other financing activities stood at $323000.0 in 2022, then gained by 22.91% to $397000.0 in 2023, then sank by 91.94% to $32000.0 in 2024, then soared by 596.88% to $223000.0 in 2025, then tumbled by 81.17% to $42000.0 in 2026.
• The last three Other financing activities figures came in at $42000.0 (Q2 2026), $78000.0 (Q1 2026), and $223000.0 (Q4 2025), per Business Quant data.